Articles from Apogee Therapeutics
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled
By Apogee Therapeutics · Via GlobeNewswire · February 3, 2025
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T.
By Apogee Therapeutics · Via GlobeNewswire · January 29, 2025
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025
By Apogee Therapeutics · Via GlobeNewswire · December 10, 2024
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
By Apogee Therapeutics · Via GlobeNewswire · December 2, 2024
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET.
By Apogee Therapeutics · Via GlobeNewswire · November 29, 2024
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments
By Apogee Therapeutics · Via GlobeNewswire · November 18, 2024
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile
By Apogee Therapeutics · Via GlobeNewswire · November 12, 2024
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management will participate at the following investor conferences.
By Apogee Therapeutics · Via GlobeNewswire · November 4, 2024
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently approved treatments for moderate-to-severe AD
By Apogee Therapeutics · Via GlobeNewswire · October 24, 2024
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology’s (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for the treatment for atopic dermatitis and other inflammatory diseases.
By Apogee Therapeutics · Via GlobeNewswire · October 16, 2024
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on Wednesday, September 18, 2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T.
By Apogee Therapeutics · Via GlobeNewswire · September 12, 2024
![](https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png)
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy, pricing and policy.
By Apogee Therapeutics · Via GlobeNewswire · September 9, 2024
![](https://mms.businesswire.com/media/20230622933401/en/1826448/5/apogee-logo-full-color-rgb-HIGH.jpg)
Apogee Therapeutics, a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease and related inflammatory and immunology indications, today announced the appointments of Jennifer Fox and William “BJ” Jones, seasoned executives in the biotechnology industry, to its board of directors. Ms. Fox will also serve as chair of the company’s audit committee. Additionally, Apogee announced the appointment of Rebecca Dabora, Ph.D., an expert in chemistry, manufacturing and controls (CMC), as chief technology officer.
By Apogee Therapeutics · Via Business Wire · June 22, 2023